UK markets close in 2 hours 6 minutes

Kiromic BioPharma, Inc. (KRBP)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.60000.0000 (0.00%)
At close: 02:56PM EDT

Kiromic BioPharma, Inc.

7707 Fannin Street
Suite 200
Houston, TX 77054
United States
832 968 4888

Full-time employees35

Key executives

NameTitlePayExercisedYear born
Mr. Pietro Bersani CPA, J.D.CEO & Director891.69kN/A1968
Mr. Brian HungerfordChief Financial Officer160.69kN/A1976
Dr. Leonardo Mirandola Ph.D.Chief Scientific Officer & Interim COO383.32kN/A1982
Dr. Scott Dahlbeck M.D., Pharm.D., PharmDChief of Staff359.08kN/A1962
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Kiromic BioPharma, Inc., a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

Corporate governance

Kiromic BioPharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.